Corticotropin-releasing factor (CRF) neurons, also known as corticoliberin neurons, are critical components of the brain's stress response system and play essential roles in neuroendocrine regulation, autonomic function, and behavior. These specialized neurons synthesize and secrete CRF (also called corticoliberin), a 41-amino acid peptide that serves as the primary hypothalamic activator of the hypothalamic-pituitary-adrenal (HPA) axis. Beyond their classical role in stress physiology, CRF neurons have emerged as key players in neurodegenerative processes, neuroinflammation, and psychiatric comorbidities associated with neurological disorders.[1][2]
| Property | Value |
|---|---|
| Category | Stress Response / Neuroendocrine Neurons |
| Primary Location | Paraventricular nucleus of hypothalamus (PVN) |
| Secondary Locations | Central amygdala, bed nucleus of stria terminalis (BNST), locus coeruleus |
| Cell Types | Parvocellular neurosecretory CRF neurons, CRF interneurons |
| Primary Peptide | CRF (41 amino acids) |
| Related Peptides | Urocortin 1, 2, 3 |
| Key Markers | CRH, CRHR1, CRHR2, AVP (co-expressed) |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:4072021 | corticotropin-releasing neuron |
The majority of CRF neurons reside in the parvocellular division of the PVN. These neurons project to the median eminence, releasing CRF into the hypothalamo-hypophyseal portal system to stimulate adrenocorticotropic hormone (ACTH) release from anterior pituitary corticotrophs.[3]
CRF neurons in the central amygdala and bed nucleus of stria terminalis are involved in fear, anxiety, and emotional memory. These populations do not project to the portal system but instead modulate local circuits and downstream targets including the locus coeruleus and dorsal raphe.[4]
CRF binding to CRHR1/CRHR2 activates adenylate cyclase via Gs protein, increasing intracellular cAMP. This activates protein kinase A (PKA), which:
CRF receptor activation also triggers MAPK/ERK signaling through:
Emerging evidence suggests CRF activates PI3K/Akt signaling, which:
Chronic HPA axis hyperactivity in AD leads to:
CRF alterations in PD include:
In HD models:
HPA axis dysfunction in ALS:
CRF neurons play a central role in neuroimmune crosstalk:
CSF CRF levels may predict stress-related cognitive decline
Salivary cortisol patterns reflect HPA axis function
CRHR1 genetic variants (rs110402, rs242924) influence stress susceptibility[17]
Hypothalamic PVN CRH Neurons
HPA Axis
Neuroinflammation Stress Responsemechanisms/stress-response-neurodegene- Microgliatisol-Tau Pathway
Microglia Paraventricular Hypothalamic Neurons
Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. 1981. ↩︎
Holsboer F. [The stress response and open-field behavior in transgenic mice expressing corticotropin-releasing hormone](https://doi.org/10.1016/S0022-3956(99). 1999. ↩︎
Swanson LW, Sawchenko PE, Rivier J, Vale WW. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. 1983. ↩︎
Gray TS, Bingaman EW. The amygdala: corticotropin-releasing factor, steroids, and stress. 1996. ↩︎
Zorrilla EP, Koob GF. Progress in corticotropin-releasing factor-1 antagonist development. 2010. ↩︎
Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. 2004. ↩︎
Grammatopoulos DK, Chrousos GP. [Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists](https://doi.org/10.1016/S1043-2760(02). 2002. ↩︎
Bruijnzeel AW, Gold MS. The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. 2005. ↩︎
Jovanovic N, Jovanovic S. Role of corticotropin-releasing factor in stress-related psychiatric disorders. 2021. ↩︎
Notarianni E. Hypercortisolemia and glucocorticoid receptor-signaling insufficiency in Alzheimer's disease pathogenesis. 2013. ↩︎
Wang J, Tanila H, Puoliväli J, Kadish I, van Groen T. Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. 2003. ↩︎
Hemmerle AM, Dickerson JW, Herman JP, Seroogy KB. Stress exacerbates experimental Parkinson's disease in rats. 2014. ↩︎
Heikkinen T, Pussinen R, Jolkkonen J, Koistinaho J. Effects of corticotropin-releasing factor receptor 1 antagonism on behavioural and molecular changes in Huntington's disease models. 2020. ↩︎
Paganoni S, Schwarzschild M. Urate as a marker of risk and progression of neurodegenerative disease. 2017. ↩︎
Wu Y, Zhang Y, Zhang J, Wei X, Zhou Y, Wang X, et al. Corticotropin-releasing hormone promotes NLRP3 inflammasome activation in Parkinson's disease. 2023. ↩︎
Feyissa DD, Aßmann A, Richter N, Duan W, Lang UE. Effects of corticotropin releasing hormone on microglial activation and neuroinflammation. 2021. ↩︎
Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. 2009. ↩︎